Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Update

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) was the recipient of a large decline in short interest in December. As of December 15th, there was short interest totaling 100,401 shares, a decline of 40.4% from the November 30th total of 168,471 shares. Based on an average daily volume of 91,627 shares, the short-interest ratio is presently 1.1 days. Approximately 0.7% of the company’s shares are sold short. Approximately 0.7% of the company’s shares are sold short. Based on an average daily volume of 91,627 shares, the short-interest ratio is presently 1.1 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genenta Science in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Institutional Investors Weigh In On Genenta Science

An institutional investor recently bought a new position in Genenta Science stock. Citadel Advisors LLC purchased a new stake in Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 12,486 shares of the company’s stock, valued at approximately $41,000. Citadel Advisors LLC owned approximately 0.07% of Genenta Science as of its most recent filing with the SEC. Institutional investors and hedge funds own 15.13% of the company’s stock.

Genenta Science Price Performance

GNTA stock remained flat at $1.46 during midday trading on Friday. 50,545 shares of the company’s stock were exchanged, compared to its average volume of 90,953. The company’s 50-day moving average price is $2.15 and its 200 day moving average price is $3.01. Genenta Science has a 12 month low of $1.28 and a 12 month high of $10.00.

Genenta Science (NASDAQ:GNTA) last posted its quarterly earnings results on Friday, October 10th. The company reported ($0.10) earnings per share for the quarter. On average, research analysts anticipate that Genenta Science will post -0.93 EPS for the current year.

About Genenta Science

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.